PMA device
Cervista Hpv 16/18
Hologic, Inc. · Kit, Dna Detection, Human Papillomavirus (MAQ, Class III) · First FDA decision Mar 4, 2014, newest Apr 29, 2014Cervical cancer and HPV
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Cervista Hpv 16"
MAUDE reports
0
Brand "Cervista Hpv 16", since 2015
PubMed studies
8
Mentioning "Cervista Hpv 16"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Cervista Hpv 16/18
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- CERVISTA HPV 16/18PMA supplement
P080015-S009 · Decided Apr 29, 2014 · 272 days after receipt · Normal 180 Day Track No User Fee
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Cervical Cancer with Human Papillomavirus (HPV) TestingNational analysisReview closedCAG-00442NUpdated Sep 22, 2026
- Screening for Cervical Cancer with Human Papillomavirus (HPV)National determinationOn the books210.2.1Updated Jun 17, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "Cervista Hpv 16", any status and sponsor, newest update first.
No registered device study names "Cervista Hpv 16".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Cervista Hpv 16", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MAQ
310 reports: 306 malfunction, 3 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Cervista Hpv 16"[tiab]. The summary above synthesizes these.
- Analytical performance of cervista HPV 16/18 in SurePath pap specimens.
Guo M, Khanna A, Feng J, et al. · Diagn Cytopathol · 2015
- Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology.
Kurian EM, Caporelli ML, Baker S, et al. · Am J Clin Pathol · 2011Comparative Study
- Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples.
Bartholomew DA, Luff RD, Quigley NB, et al. · J Clin Virol · 2011Multicenter Study, Research Support, Non-U.S. Gov't
- Age-stratified performance of the Cervista HPV 16/18 genotyping test in women with ASC-US cytology.
Einstein MH, Garcia FA, Mitchell AL, et al. · Cancer Epidemiol Biomarkers Prev · 2011Comparative Study, Multicenter Study
- Incorporation of Cervista Human Papillomavirus 16/18 Assay Into Algorithms for Classifying Human Papillomavirus Status in Formalin-Fixed, Paraffin-Embedded Head and Neck Squamous Carcinoma Specimens.
Guo M, Khanna A, Wang J, et al. · Arch Pathol Lab Med · 2019
- Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media.
Min KJ, So KA, Lee J, et al. · J Gynecol Oncol · 2012
- Triage of women with negative cytology and positive high-risk HPV: an analysis of data from the SHENCCAST II/III studies.
Goodrich SK, Pretorius RG, Du H, et al. · J Low Genit Tract Dis · 2014Research Support, Non-U.S. Gov't
- Assessment of clinical and analytical performance characteristics of an HPV genotyping test.
Schutzbank TE, Ginocchio CC · Diagn Cytopathol · 2012Research Support, Non-U.S. Gov't, Review
Other devices of this type
Also filed under product code MAQ.
- cobas HPVRoche Molecular Systems, Inc. · PMA 2026
- BD Onclarity HPV Assay Reagent Pack (SKU 444075) and BD COR HPV Extraction Trough (SKU 444074)Becton, Dickinson and Company · PMA 2026
- Digene Hybrid Capture 2 (HC2) Hpv Dna TestsQiagen Gaithersburg, Inc. · PMA 2015
- Alinity m HR HPVAbbott Molecular, Inc. · PMA 2026
- Cervista Hpv Hr and Genfind KitHologic, Inc. · PMA 2014
- Onclarity HPV AssayBecton, Dickinson and Company · PMA 2025
- Digene HC2 High Risk Hpv Dna Test and Digene HC2 Hpv Dna TestQiagen Gaithersburg, Inc. · PMA 2014
- Digene Hybrid CAPTURE2Qiagen Gaithersburg, Inc. · PMA 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.